@inbook{e0c7665ed9b14046b95f4e647ccf56af,
title = "Trophic factors therapy in Parkinson's disease",
abstract = "Parkinson's disease (PD) is a progressive, neurodegenerative disorder for which there is currently no effective neuroprotective therapy. Patients are typically treated with a combination of drug therapies and/or receive deep brain stimulation to combat behavioral symptoms. The ideal candidate therapy would be the one which prevents neurodegeneration in the brain, thereby halting the progression of debilitating disease symptoms. Neurotrophic factors have been in the forefront of PD research, and clinical trials have been initiated using members of the GDNF family of ligands (GFLs). GFLs have been shown to be trophic to ventral mesencephalic cells, thereby making them good candidates for PD research. This paper examines the use of GDNF and neurturin, two members of the GFL, in both animal models of PD and clinical trials.",
keywords = "GDNF, Parkinson's disease, clinical trials, gene therapy, glial cell line-derived neurotrophic factor family ligands, neurotrophic factors, neurturin",
author = "Shilpa Ramaswamy and Soderstrom, {Katherine E.} and Kordower, {Jeffrey H.}",
year = "2009",
doi = "10.1016/S0079-6123(09)17514-3",
language = "English (US)",
isbn = "9780123745118",
series = "Progress in Brain Research",
pages = "201--216",
editor = "Joost Verhaagen and Elly Hol and Inge Huitenga and Jan Wijnholds and Arthur Bergen and Gerald Boer and Dick Swaab",
booktitle = "Neurotherapy",
}